This is targeted continuation round 3 in the same session. Do not restart the task, open a new session, edit files, read another participant's output, or broaden scope.

Hard boundaries:
- Work read-only inside the current workbench workspace.
- Do not read or modify product/runtime, medical-writing, real-project, or 8911 surfaces.
- Do not call providers, start services, or edit any source/review/run file.
- The report is runner-owned. Return the complete report in your final response; never write it with tools.

Read these files only:
- `reviews/medical_monitoring_r4_risk_coverage_matrix_v1_20260810.md`
- `runs/conference/medical_monitoring_r4_coverage_matrix_20260810/general_grok45.md`

Runner-managed report path: `runs/conference/medical_monitoring_r4_coverage_matrix_20260810/general_grok45.md`

Codex accepted your prior VETO and patched `reviews/medical_monitoring_r4_risk_coverage_matrix_v1_20260810.md`. Re-read the current artifact and perform a delta-only acceptance review against your own prior findings:

- F-P1-01: L0 execution coverage, exclusive L1 medical disposition, L1b evidence polarity and L3 lifecycle must be orthogonal; `counterevidence` must not be a sixth disposition.
- F-P1-02: EvaluationUnit identity, expected-set hash, exact denominator equation and join invariants must be deterministic.
- F-P1-03: L0/L1/L3 `not_evaluable` and `not_applicable` meanings must not collide.
- F-P1-04: R2 must be the sole lifecycle authority; R1/Design `resolved_by_data`, lineage change, identity ambiguity and terminal not-evaluable must map explicitly.
- F-P1-05: event intensity, seriousness and monitoring priority must remain separate, with explicit R2 severity projection and high-risk close gate.
- F-P2-01..03: R3 partial-date binding, numeric joins and domain-grain source authority must be explicit.
- F-P3/P4 advice: D01 semantic roles and versioned match strategy, non-issue adjudication, D09 denominator gate, projection-only boundary, anti-invariants and stable engineering codes must be explicit.

Inspect the full common-contract sections and the changed D01-D10 table labels, then focus on D01, D09, §6 and §7. For every prior finding state `RESOLVED`, `PARTIAL`, or `UNRESOLVED`, cite the current exact locator and explain only the remaining gap. Do not invent new R5/R7/product/security requirements. A new finding is allowed only if the patch created a direct contradiction in the same freeze scope.

Return a complete replacement Markdown report for this role, preserving evidence, inference, recommendation and uncertainty separately. End with exactly one final line: `VERDICT: ACCEPT` or `VERDICT: VETO`. ACCEPT requires no unresolved P0-P3. Codex remains final authority.
